NCT03404726 - A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

January 26, 2021

Study Completion Date

January 26, 2021

Conditions

Leukemia

Interventions

DRUG

BAY2402234

BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

19107

Thomas Jefferson University, Philadelphia

37232

Vanderbilt University Medical Center, Nashville

94805

Institut Gustave Roussy, Villejuif

10467-2490

Montefiore Medical Center, The Bronx